News and Events

Below are our most recent news releases. Click on a news item to read more.

Apr 26, 2022 – MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC)

Mar 16, 2022 – MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies

Mar 15, 2022 – MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC

Nov 09, 2021 – MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

Oct 14, 2021 – MAIA Biotechnology, Inc. Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies

Sep 28, 2021 – MAIA Biotechnology, Inc. Announces the Appointment of Steven M. Chaouki to Its Board of Directors

Sep 15, 2021 – MAIA Biotechnology, Inc. Announces Formation of Scientific Advisory Board

Aug 17, 2021 – MAIA Biotechnology, Inc. Appoints Joseph F. McGuire as Chief Financial Officer and Provides Corporate Update

Aug 04, 2021 – MAIA Biotechnology, Inc. Announces Additions to Executive Team and Board of Directors

May 19, 2021 – MAIA Biotechnology, Inc. Raises $8.0 Million Financing to Advance Pipeline of Targeted Immuno-Oncology Studies

Mar 25, 2021 – MAIA Biotechnology to Present at Upcoming Investor Conferences

Feb 02, 2021 – MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo^® (cemiplimab) in Advanced Non-Small Cell Lung Cancer

Jul 07, 2020 – MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO